Amino acids in type 2 diabetes

The fate of incomplete amino acid metabolism in type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON20131

Enrollment

Registered

2013-09-20

Start date

2013-10-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obesity type 2 diabetes metabolic syndrome

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, the participant must meet all of the following criteria: - male or postmenopausal females - 45-65 years - BMI 27 kg/m2 - stable dietary habits (no weight loss/gain >5kg in the last 3 months) - stable physical activity levels for at least 6 months - participants without T2DM should be normal glucose tolerant (OGTT with fasting plasma glucose <6.1 mmol/l and 2h glucose of <7.8 mmol/l - FDR will be included on the presence of family history of type 2 diabetes Patients with T2DM: - non-insulin dependent patients diagnosed with T2DM for at least 1.5 years using sulphonylurea (i.e.glibenclamide, gliclazide, glimepiride en tolbutamide), and/or biguaniden (metformin) therapy for at least 6 months with a constant dose for at least 2 months - patients should have a HbA1c < 8.5% - patients will be included when having no active diabetes-related co-morbidities like cardiovascular diseases, diabetic foot, polyneuropathy, retinopathy - subjects will be included only when the dependent medical doctor of this study approves participation after evaluating all data obtained during the screening (visit 1)

Exclusion criteria

Exclusion criteria: - participants will be excluded when being diagnosed with active cardiovascular disease, diabetic foot, polyneuropathy, retinopathy - participants will be excluded when having uncontrolled hypertension - participants following a vegetarian diet or having an allergy against soya - participants with contra-indication for MRI

Design outcomes

Primary

Measure	Time frame
i) leucine oxidation rate (umol kg-1 min-1) ii) insulin sensitivity (umol kg-1 min-1)	—

Secondary

Measure	Time frame
i) mitochondrial function (O2-flux pmol mg-1 s-1) ii) fat accumulation in the liver (%)	—

Contacts

Public ContactE. Phielix

Maastricht University Department of Human Biology

esther.phielix@hb.unimaas.nl+31 (0)43-388 14 05

Outcome results